Atacicept Injection 150 mg Suppliers & Bulk Manufacturers

Available Forms: Autoinjector (subcutaneous)

Available Strengths: 150 mg

Reference Brands: Trutakna (Vera Therapeutics)

Atacicept (Trutakna, Vera Therapeutics) is a weekly self-injected fusion protein that blocks both BAFF and APRIL, approved by the US FDA in July 2026 to reduce proteinuria in IgA nephropathy. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Atacicept Injection? List it or send an offer →

Product Description:

Atacicept is a fusion protein built from the TACI receptor. It mops up two B-cell signals, BAFF and APRIL, which together keep alive the B cells and plasma cells that make the abnormal IgA1 behind IgA nephropathy. Blocking both signals lowers the abnormal IgA, the immune deposits in the kidney and the protein in the urine.

The US FDA granted atacicept accelerated approval as Trutakna in July 2026 to reduce proteinuria in adults with primary IgA nephropathy at risk of disease progression. It is self-injected once a week as 150 mg from an autoinjector. Continued approval depends on confirmation of benefit on kidney function.

Sourcing and licensing notes. Atacicept is patented and made only by Vera Therapeutics; there is no biosimilar. The APRIL-only antibody sibeprenlimab is also listed on PharmaTradz. We confirm registration status for each destination before quoting.

How Atacicept Injection is supplied today, and licensing ahead of patent expiry

Atacicept Injection is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Atacicept Injection, hold a dossier for it or want to license it, talk to us.

Where atacicept is approved

Checked 3 Oct 2026

Market	Status	Brand · regulator · date
United States	Approved	Trutakna · FDA · Jul 2026 (accelerated)
Generic / biosimilar	None	None approved as of the check date

Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Atacicept Injection supply →

Back to Listing